Elevation Oncology (ELEV) Stock Forecast, Price Target & Predictions
ELEV Stock Forecast
Elevation Oncology stock forecast is as follows: an average price target of $9.00 (represents a 1378.32% upside from ELEV’s last price of $0.61) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ELEV Price Target
The average price target for Elevation Oncology (ELEV) is $9.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $8.00. This represents a potential 1378.32% upside from ELEV's last price of $0.61.
ELEV Analyst Ratings
According to 5 Wall Street analysts, Elevation Oncology's rating consensus is 'Buy'. The analyst rating breakdown for ELEV stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Elevation Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 31, 2024 | Biren Amin | Piper Sandler | $10.00 | $4.07 | 145.70% | 1542.58% |
| May 13, 2024 | Sudan Loganathan | Stephens | $8.00 | $3.54 | 125.99% | 1214.06% |
The latest Elevation Oncology stock forecast, released on May 31, 2024 by Biren Amin from Piper Sandler, set a price target of $10.00, which represents a 145.70% increase from the stock price at the time of the forecast ($4.07), and a 1542.58% increase from ELEV last price ($0.61).
Elevation Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $9.00 |
| Last Closing Price | $0.61 | $0.61 | $0.61 |
| Upside/Downside | -100.00% | -100.00% | 1378.32% |
In the current month, the average price target of Elevation Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elevation Oncology's last price of $0.61. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 28, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 28, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 31, 2024 | Piper Sandler | - | Overweight | Initialise |
| May 13, 2024 | Stephens | - | Overweight | Initialise |
| May 30, 2023 | Telsey Advisory | - | Outperform | Upgrade |
| May 30, 2023 | MoffettNathanson | - | Outperform | Upgrade |
Elevation Oncology's last stock rating was published by Cowen & Co. on Aug 06, 2024. The company gave ELEV a "Buy" rating, the same as its previous rate.
Elevation Oncology Financial Forecast
Elevation Oncology Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Elevation Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELEV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Elevation Oncology EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ELEV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Elevation Oncology's previous annual EBITDA (undefined) of $NaN.
Elevation Oncology Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-12.54M | $-12.25M | $-11.51M | $-11.36M | $-11.80M | $-11.21M | $-13.19M |
| High Forecast | $-12.54M | $-12.25M | $-11.51M | $-11.36M | $-11.80M | $-11.21M | $-13.19M |
| Low Forecast | $-12.54M | $-12.25M | $-11.51M | $-11.36M | $-11.80M | $-11.77M | $-13.19M |
| Surprise % | - | - | - | - | - | - | - |
Elevation Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELEV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Elevation Oncology SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Elevation Oncology's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ELEV last annual SG&A of $NaN (undefined).
Elevation Oncology EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.21 | $-0.21 | $-0.20 | $-0.19 | $-0.20 | $-0.19 | $-0.22 |
| High Forecast | $-0.21 | $-0.21 | $-0.20 | $-0.19 | $-0.20 | $-0.19 | $-0.22 |
| Low Forecast | $-0.21 | $-0.21 | $-0.20 | $-0.19 | $-0.20 | $-0.20 | $-0.22 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Elevation Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELEV previous annual EPS of $NaN (undefined).
ELEV Forecast FAQ
Is Elevation Oncology a good buy?
Yes, according to 5 Wall Street analysts, Elevation Oncology (ELEV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ELEV's total ratings.
What is ELEV's price target?
Elevation Oncology (ELEV) average price target is $9 with a range of $8 to $10, implying a 1378.32% from its last price of $0.609. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Elevation Oncology stock go up soon?
According to Wall Street analysts' prediction for ELEV stock, the company can go up by 1378.32% (from the last price of $0.609 to the average price target of $9), up by 1542.58% based on the highest stock price target, and up by 1214.06% based on the lowest stock price target.
Can Elevation Oncology stock reach $1?
ELEV's average twelve months analyst stock price target of $9 supports the claim that Elevation Oncology can reach $1 in the near future.
What are Elevation Oncology's analysts' financial forecasts?
Elevation Oncology's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-36.208M (high $-36.208M, low $-36.769M), average SG&A $0 (high $0, low $0), and average EPS is $-0.614 (high $-0.614, low $-0.623). ELEV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-47.657M (high $-47.657M, low $-47.657M), average SG&A $0 (high $0, low $0), and average EPS is $-0.807 (high $-0.807, low $-0.807).